Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 6, 2012, Pages 1007-1016

  Misri, Ripen ^a   Meier, Dominik ^b   Yung, Andrew C ^a   Kozlowski, Piotr ^a   Häfeli, Urs O ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dual modality; Imaging; MRI; Nanoparticles; SPECT

Indexed keywords

BIOPROBE; CANCER IMAGING; CANCER RESEARCH; CLINICAL SETTINGS; CONTRAST MATERIAL; DIAGNOSTIC TOOLS; DUAL MODALITY; EARLY DIAGNOSIS; FUNCTIONALIZED; IMAGING INFORMATION; MAGNETIC NANOPARTICLES; SIGNAL SENSITIVITY; SPECT; SUPERPARAMAGNETIC IRON OXIDES; TREATMENT PLANNING; TUMOR VISUALIZATION;

ANTIBODIES; DIAGNOSIS; DISEASES; IMAGING TECHNIQUES; IRON OXIDES; MAGNETIC PROPERTIES; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NANOPARTICLES; SUPERPARAMAGNETISM; TUMORS; VISUALIZATION;

SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

ANTIBODY; INDIUM 111; MESOTHELIN; MESOTHELIN ANTIBODY; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DISTRIBUTION; MOUSE; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CELL LINE, TUMOR; CONTRAST MEDIA; DEXTRANS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS, EXPERIMENTAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84864086157     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.10.013     Document Type: Article

References (50)

1. Marzola P., Osculati F., Sbarbati A. High field MRI in preclinical research. Eur J Radiol 2003, 48:165-170.
2. Wagenaar D.J., Kapusta M., Li J., Patt B.E. Rationale for the combination of nuclear medicine with magnetic resonance for pre-clinical imaging. Technol Cancer Res Treat 2006, 5:343-350.
3. Hamamura M.J., Ha S., Roeck W.W., Muftuler L.T., Wagenaar D.J., Meier D., et al. Development of an MR-compatible SPECT system (MRSPECT) for simultaneous data acquisition. Phys Med Biol 2010, 55:1563-1575.
4. Goetz C., Breton E., Choquet P., Israel-Jost V., Constantinesco A. SPECT low-field MRI system for small-animal imaging. J Nucl Med 2008, 49:88-93.
5. Catana C., Procissi D., Wu Y., Judenhofer M.S., Qi J., Pichler B.J., et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A 2008, 105:3705-3710.
6. Pichler B.J., Wehrl H.F., Judenhofer M.S. Latest advances in molecular imaging instrumentation. J Nucl Med 2008, 49(Suppl 2):5S-23S.
7. Argani P., Iacobuzio-Donahue C., Ryu B., Rosty C., Goggins M., Wilentz R.E., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001, 7:3862-3868.
8. Hassan R., Kreitman R.J., Pastan I., Willingham M.C. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005, 13:243-247.
9. Liu S., Jia B., Qiao R., Yang Z., Yu Z., Liu Z., et al. A novel type of dual-modality molecular probe for MR and nuclear imaging of tumor: preparation, characterization and in vivo application. Mol Pharm 2009, 6:1074-1082.
10. Chen T.J., Cheng T.H., Chen C.Y., Hsu S.C., Cheng T.L., Liu G.C., et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009, 14:253-260.
11. Cerdan S., Lotscher H.R., Kunnecke B., Seelig J. Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn Reson Med 1989, 12:151-163.
12. Lijowski M., Caruthers S., Hu G., Zhang H., Scott M.J., Williams T., et al. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol 2009, 44:15-22.
13. Kryza D., Taleb J., Janier M., Marmuse L., Miladi I., Bonazza P., et al. Biodistribution study of nanometric hybrid gadolinium oxide particles as a multimodal SPECT/MR/optical imaging and theragnostic agent. Bioconjug Chem 2011, 22:1145-1152.
14. 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors. Nucl Med Biol 2011, 38:885-896.
15. Rudershausen S., Gruttner C., Frank M., Teller J., Westphal F. Multifunctional superparamagnetic nanoparticles for life sciences applications. Eur Cell Mater 2002, 3:81-83.
16. Collins T.J. ImageJ for microscopy. Biotechniques 2007, 43:25-30.
17. Lee H., Lee E., Kim do K., Jang N.K., Jeong Y.Y., Jon S. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 2006, 128:7383-7389.
18. Lee C.M., Jeong H.J., Kim E.M., Kim D.W., Lim S.T., Kim H.T., et al. Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo. Magn Reson Med 2009, 62:1440-1446.
19. Chowdhury P.S., Viner J.L., Beers R., Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998, 95:669-674.
20. Maeda H., Wu J.C., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
21. Otsuji E., Kuriu Y., Okamoto K., Ichikawa D., Hagiwara A., Ito H., et al. Monoclonal antibody A7 coupled to magnetic particles as a contrast enhancing agent for magnetic resonance imaging of human colorectal carcinoma. Cancer Immunol Immunother 2006, 55:728-733.
22. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., et al. TAT peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000, 18:410-414.
23. Kaufner L., Cartier R., Wüstneck R., Fichtner I., Pietschmann S., Bruhn H., et al. Poly(ethylene oxide)- block -poly(glutamic acid) coated maghemite nanoparticles: in vitro characterization and in vivo behaviour. Nanotechnology 2007, 18:115710.
24. Torres Martin de Rosales R., Tavare R., Glaria A., Varma G., Protti A., Blower P.J. (99m)Tc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconjug Chem 2011.
25. Bligh S.W., Sadler P.J., Marriott J.A., Latham I.A., Kelly J.D. Characterization and in vivo distribution of 99mTc- and 111In-labelled magnetite. Int J Radiat Appl Instrum A 1989, 40:751-757.
26. Saini S., Stark D.D., Hahn P.F., Wittenberg J., Brady T.J., Ferrucci J.T. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987, 162:211-216.
27. Stark D.D., Weissleder R., Elizondo G., Hahn P.F., Saini S., Todd L.E., et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988, 168:297-301.
28. Weissleder R., Lee A.S., Khaw B.A., Shen T., Brady T.J. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992, 182:381-385.
29. Tiefenauer L.X., Kuhne G., Andres R.Y. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug Chem 1993, 4:347-352.
30. Suwa T., Ozawa S., Ueda M., Ando N., Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer 1998, 75:626-634.
31. Suzuki M., Honda H., Kobayashi T., Wakabayashi T., Yoshida J., Takahashi M. Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles. Noshuyo Byori 1996, 13:127-132.
32. Tanimoto A., Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol 2006, 58:200-216.
33. Jain T.K., Foy S.P., Erokwu B., Dimitrijevic S., Flask C.A., Labhasetwar V. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials 2009, 30:6748-6756.
34. Gossuin Y., Gillis P., Hocq A., Vuong Q.L., Roch A. Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1:299-310.
35. Ma H.L., Xu Y.F., Qi X.R., Maitani Y., Nagai T. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm 2008, 354:217-226.
36. Barick K.C., Aslam M., Prasad P.V., Dravid V.P., Bahadur D. Nanoscale assembly of amine functionalized colloidal iron oxide. J Magn Magn Mater 2009, 321:1529-1532.
37. Sung C.K., Hong K.A., Lin S., Lee Y., Cha J., Lee J.K., et al. Dual-modal nanoprobes for imaging of mesenchymal stem cell transplant by MRI and fluorescence imaging. Korean J Radiol 2009, 10:613-622.
38. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
39. Glaus C., Rossin R., Welch M.J., Bao G. In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem 2010, 21:715-722.
40. Nahrendorf M., Zhang H., Hembrador S., Panizzi P., Sosnovik D.E., Aikawa E., et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379-387.
41. Ho M., Onda M., Wang Q.C., Hassan R., Pastan I., Lively M.O. Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev 2006, 15:1751.
42. Congdon C.C. The destructive effect of radiation on lymphatic tissue. Cancer Res 1966, 26:1211-1220.
43. Kurnick N.B., Nokay N. Changes induced in the mouse spleen by graded doses of total-body x-irradiation. Radiat Res 1962, 17:140-144.
44. Cobb L.M., Butler S.A. Treatment of the murine lymphoma A31 with intravenous, sterilized, 114mIn-loaded A31 cells. Radiother Oncol 1987, 10:217-230.
45. Arbab A.S., Bashaw L.A., Miller B.R., Jordan E.K., Lewis B.K., Kalish H., et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 2003, 229:838-846.
46. Ho M., Bera T.K., Willingham M.C., Onda M., Hassan R., FitzGerald D., et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007, 13:1571-1575.
47. Hassan R., Viner J.L., Wang Q.C., Margulies I., Kreitman R.J., Pastan I. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000, 23:473-479.
48. Jun Y.W., Huh Y.M., Choi J.S., Lee J.H., Song H.T., Kim S., et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005, 127:5732-5733.
49. Wehrl H.F., Judenhofer M.S., Wiehr S., Pichler B.J. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 2009, 36(Suppl 1):S56-S68.
50. Hamamura M.J., Ha S., Roeck W.W., Wagenaar D.J., Meier D., Patt B.E., et al. Initial investigation of preclinical integrated SPECT and MR imaging. Technol Cancer Res Treat 2010, 9:21-28.